Zimmer Biomet has secured 510(k) clearance from the US Food and Drug Administration (FDA) for its ROSA ONE Spine System in robotically assisted surgeries.
The company’s craniomaxillofacial (CMF) and thoracic and surgery assisting technology group president Aure Bruneau said: “ROSA ONE Spine functions as a dual robotics and navigation technology solution for minimally invasive and complex thoracolumbar spine procedures.”
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
ROSA ONE Spine’s surgical navigation system features a real-time patient tracking capability and 3D intra-operative planning software for improved implant placement.
The new device expands the company’s suite of ROSA ONE systems, offers treatment of neurosurgical, spinal and knee pathologies in one platform.
The FDA cleared ROSA ONE Knee in January this year for use in robotically assisted total knee replacements. This device features 3D pre-operative planning tools and real-time, intraoperative data on soft-tissue and bone anatomy.
The knee surgery device is intended to improve bone cut accuracy and a range of motion gap analyses to potentially boost flexion and restore natural joint movement.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataROSA ONE Brain received US regulatory clearance in February for neurosurgical minimally invasive procedures such as biopsies and deep brain stimulation.
In addition to surgical systems, Zimmer Biomet portfolio includes orthopaedic reconstructive, sports medicine, extremities and trauma products, among other medical devices.
